Aviragen Therapeutics (AVIR) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Join SI Premium – FREE
Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.38), $0.11 better than the analyst estimate of ($0.49).
For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- JPMorgan Upgrades Lithium Americas Corp. (LAC:CN) (LAC) to Overweight
- Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
